R&D ARTICLES

• Why COGs Will Demand More Attention From Biosimilar Makers

  Without continued innovation in the manufacturing and analytical components of biosimilar development, the biosimilar value proposition becomes less feasible for pharma manufacturers.

• Why Is Antibiotic Development In The U.S. Disappearing?

  Today, 95 percent of antibiotics in development are being studied by smaller biotechs, including Paratek Pharmaceuticals. Today, the company is on a strong trajectory, but its ups and downs show why antibiotic companies fail and few new antibiotics reach patients.

• The Viral Startup

  ViralClear, formed in March 2020 to obtain a drug whose potential use against COVID-19 already has substantial support in evidence. The company is employing considerable industry expertise to move it into clinical development.

• Working With The U.S Army To Achieve Tech Transfer Success

  Many pharmas or biotechs may not know the opportunities available from working with the U.S. Army on license agreements or Collaborative Research and Development Agreements (CRADAs). Here’s what to know about the Medical Technology Transfer (MTT) office.

• Leadership Competencies For Rare Disease Therapies

  Traditionally, firms seek out leadership candidates who are strong "cultural fits." In the case of Big Pharma hiring experts in gene and cell therapies, however, they should be looking for "misfits" if you will.

• Meeting Business Challenges By Design, Not Accident

  The story of the business challenges faced by Diasome Pharmaceuticals as it develops its insulin-enhancing delivery technology, which seeks to correct a long-known deficiency in subcutaneous injection of insulin.

• The Unique Challenges Facing Cannabis-based Pharma

  Now that the FDA has finally approved the first-ever pharmaceutical derived from the cannabis plant, will drug development — and success — in this niche finally take off?

• Germany’s Plan To Foster And Grow Biopharma Innovation

  In Germany, bioclusters and technology parks have been created to encourage and support pharmaceutical innovation in the region.

• Biopharma Bringing RWE Into The Real World

  Real-world evidence is playing an increasingly important role throughout the drug development lifecycle—as outlined in Deloitte's latest survey on the life sciences industry's RWE capabilities— and companies are really beginning to take notice.

• J&J’s QuickFire Challenges: Crowdsourcing Innovation

  An in-depth look at J&J’s QuickFire Challenge program and how some of the winners have benefitted (and grown) beyond the cash grants.